PO.BCS01.08 · 生物信息与计算
基于扩散模型的色卡在组织学图像批次校正中的实现
Implementation of a diffusion-based color checker for histological image batch correction
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:不一致的组织制备、染色和扫描会在组织学图像中引入非生物学变异(批次效应)。这些变异导致机器学习模型学习到虚假的、位点特异性的特征,而非真实的病理模式,从而使内部性能虚高、泛化能力差,阻碍了临床应用。当前的染色归一化方法,如统计方法(Reinhard)、颜色反卷积(Macenko、Vahadane)和生成对抗网络,依赖于相对于任意"金标准"的相对归一化,这是一个根本性的局限。简单方法往往会扭曲重要的形态学细节,而先进技术仍无法去除所有位点特异性特征。
方法:我们引入了一种新颖的用于组织学图像批次校正的生成式AI工具,使用情境感知的Stable Diffusion图像修复模型,直接在全玻片图像(WSI)上生成动态局部色卡。该模型经训练可将物理色卡(即NIST可溯源颜色透射校准玻片)的数字表征修复至掩蔽的WSI区域,保留WSI的原始色彩空间,并在无外部参考的情况下建立情境感知标准。该模型使用117张Huron和119张Polaris扫描仪的IHC和H&E WSI(以物理NIST色卡的真实扫描作为基准真值)进行训练,使得后续能够进行颜色提取并将图像校正至所需的色彩空间。使用78张Huron和79张Polaris留出WSI进行验证。从Hibou病理学基础模型导出的均值池化嵌入被用于预测WSI的原始扫描仪。
结果:所提出的方法通过将任务从简单归一化转变为一种复杂的图像修复形式,缓解了批次效应。该模型利用其强大的习得先验,将图像重建为其在理想、标准化条件下应有的样貌,从而缓解位点特异性的批次效应。在校正之前,该分类器达到0.99的AUC-ROC,表明存在强烈的、非生物学的扫描仪特异性模式(批次效应)。归一化之后,同一分类器的性能下降(AUC-ROC = 0.53),证实了扫描仪特异性伪影的消除。
结论:该AI图像分析模型为计算病理学中的批次效应挑战提供了稳健的解决方案,消除了在IHC和H&E WSI判读期间对参考图像的需求。这种方法超越了相对颜色匹配,实现了颜色标准化。通过提高对技术性批次效应的稳健性并确保AI病理学模型在真实生物学信号上训练,这种方法有望加速病理学基础模型在临床前、转化和临床试验环境中的部署。
查看英文原文 English abstract
Introduction: Inconsistent tissue preparation, staining, and scanning introduce non-biological variations (batch effects) in histological images. These variations cause machine learning models to learn spurious, site-specific features instead of true pathological patterns, leading to inflated internal performance and poor generalizability and hindering clinical adoption. Current stain normalization methods, such as statistical (Reinhard), color deconvolution (Macenko, Vahadane), and generative adversarial networks, rely on relative normalization to an arbitrary "gold standard," a fundamental limitation. Simple methods often distort important morphological details, while advanced techniques still fail to remove all site-specific signatures.
Methods: We introduce a novel generative AI tool for histological image batch correction using a context-aware Stable Diffusion inpainting model to generate a dynamic localized color checker directly on whole slide images (WSIs). The model was trained to inpaint digital representations of a physical color checker (i.e., NIST Traceable Color Transmission Calibration Slide) onto the masked WSI region, preserving the WSI's original color space and establishing a context-aware standard without external references. Trained using 117 Huron and 119 Polaris scanner IHC and H&E WSIs with ground truth scans using the physical NIST color checker, the model enabled subsequent color extraction and image correction to a desired color space. Validation was performed using 78 Huron and 79 Polaris holdout WSIs. The mean-pooled embeddings derived from the Hibou pathology foundational model were used to predict the WSI's original scanner.
Results: The proposed method mitigated batch effects by transforming the task from simple normalization into a sophisticated form of image restoration. The model uses its powerful learned prior to reconstruct the image as it should appear under ideal, standardized conditions, mitigating site-specific batching.Prior to correction, this classifier achieved an AUC-ROC of 0.99, indicating the presence of strong, non-biological scanner-specific patterns (batch effects). After normalization, the performance of the same classifier dropped (AUC-ROC = 0.53), confirming the elimination of scanner-specific artifacts.
Conclusion: The AI image analysis model offers a robust solution to batch effect challenges in computational pathology, eliminating the need for a reference image during IHC and H&E WSI interpretation. Moving beyond relative color matching, this approach delivers color standardization. By improving robustness to technical batch effects and ensuring AI pathology models are trained on true biological signals, this approach is poised to accelerate the deployment of pathology foundational models across preclinical, translational, and clinical trial settings.
利益披露 Disclosure
A. Petrosyants,
BostonGene Corporation Employment, Stock Option.
V. Chopuryan,
BostonGene Corporation Employment.
V. Minkov,
BostonGene Corporation Employment.
A. Belozerova,
BostonGene Corporation Employment, Stock Option.
A. Bagaev,
BostonGene Corporation Employment, g., Board of Directors, non-salaried role), Stock Option, Patent.
V. Svekolkin,
BostonGene Corporation Employment, Stock Option, Patent.
A. Sarachakov,
BostonGene Corporation Employment, Stock Option, Patent.